LONDON (Reuters) – Novo Nordisk will begin a new late-stage trial of its experimental next-generation obesity drug CagriSema on Feb. 10, according to a www.clinicaltrials.gov entry.
The Danish drugmaker last month revealed disappointing results in a late-stage trial of CagriSema, wiping as much as $125 billion off its market value. It said then that it would initiate a new trial in 2025 but did not say when exactly.
The trial is estimated to end in November 2028, the entry shows. The company did not immediately respond to a request to comment.
(Reporting by Maggie Fick; Editing by Ros Russell)
Comments